This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
VABYSMO is the first and only FDA-approved treatment designed to block 2 causes of vision loss (VEGF and Ang-2†)
VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion (RVO).
In case of any adverse events or safety queries, please contact:
If you have a scientific query related to one of Roche's products, please contact:
†The benefit of blocking Ang-2 has not been fully determined. Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.
M-PK-00001980